[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"overweight-obesity\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:overweight-obesity":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":5},"100053403","phase-1-a-study-to-investigate-the-effects-of-zovaglutide-zt002-injection-on-qtc-interval-in-healthy-adults-100053403",false,"NCT07697846","A Study to Investigate the Effects of Zovaglutide (ZT002 Injection) on QTc Interval in Healthy Adults","Phase 1, Single-Center, Randomized, Double-Blind, Parallel-Group Placebo-Controlled（Concentration）-QTc（C-QTc）Study to Evaluate the Impact of ZT002 Injection on QTc Interval in Chinese Overweight and Obese Subjects","Inclusion Criteria:\n\n* Ability to understand the trial procedures and possible adverse events, be able and willing to provide a written informed consent;\n* Age between 18 - 45 years (both inclusive) at the time of signing of the informed consent;\n* Male (body weight \\>60.0 kg) or female (body weight \\>55.0 kg). Body mass index (BMI) 24.0 - 35.0 kg\u002Fm²(both inclusive);\n\nExclusion Criteria:\n\n* Known hypersensitivity (asthma, hypersensitivity to GLP-1 receptor agonists or excipients), or known hypersensitivity to ZT002 injection;\n* History of acute or chronic pancreatitis, or pancreatic injury.History of medullary thyroid carcinoma (MTC) or type 2 multiple endocrine neoplasia (MEN2) in personal or family history.\n* Has a history of cardiovascular diseases or risk factors predisposing to torsades de pointes (TdP); has personal or family history of any cardiac conduction abnormalities; has personal or family history of long QT syndrome (LQTS); or has a family history of sudden cardiac death.\n* Those with any type of malignant tumors within 5 years prior to screening (except cured basal cell carcinoma of the skin or carcinoma in situ of the cervix).\n* Medical history of hypoglycemia within 6 months before screening;\n* History of acute or chronic pancreatitis;\n* ECG findings exceeding thresholds at screening or prior to randomization: PR interval \\>220 ms, QRS duration \\>110 ms, heart rate (HR) \\\u003C50 bpm or \\>100 bpm, QTcF ≥450 ms; or presence of any ECG abnormalities deemed clinically significant by the investigator.\n* Glycated hemoglobin (HbA1c) ≥ 6.5% or fasting plasma glucose ≥ 7.0 mmol\u002FL at screening;\n* Aspartate aminotransferase \\> 2 × upper limit of normal (ULN), Alanine aminotransferase \\> 2 × ULN,\n* Alkaline phosphatase total bilirubin \\> 1.5 × ULN;\n* Subjects who have previously undergone gastric bariatric surgery or other weight-loss surgeries, or who plan to receive weight-loss surgery, liposuction, abdominal lipectomy, or other procedures with substantial impacts on body weight during the study.\n* Use of weight-altering medications or therapies within 3 months prior to screening.\n* Administration of any medications known to prolong QT\u002FQTc interval, alter heart rate, or carry risks of torsades de pointes (TdP) within 4 weeks prior to screening\n* Pregnant or lactating women, or subjects with a positive pregnancy test result at screening\u002Fbaseline",true,"ALL","18 Years","45 Years",{"count":21,"type":22},40,"ESTIMATED","INTERVENTIONAL",[25],"PHASE1","This study is designed to investigate the effect of treatment with Zovaglutide (ZT002 Injection) on the corrected cardiac QT interval relative to a placebo control in healthy participants.",[28],"Overweight, Obesity","NOT_YET_RECRUITING","2026-07-06",{"date":32,"type":33},"2026-07-13","ACTUAL",{"date":35,"type":22},"2026-07-18",{"date":37,"type":22},"2027-03-24",{"name":39,"class":40},"Beijing QL Biopharmaceutical Co.,Ltd","INDUSTRY"]